Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950170-25-081739
Filing Date
2025-06-04
Accepted
2025-06-04 17:06:46
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 10379
  Complete submission text file 0000950170-25-081739.txt   12125
Mailing Address 451 D STREET, 5TH FLOOR BOSTON MA 02210
Business Address 451 D STREET, 5TH FLOOR BOSTON MA 02210 (857) 209-0050
Elicio Therapeutics, Inc. (Subject) CIK: 0001601485 (see all company filings)

EIN.: 113430072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-93548 | Film No.: 251024010
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 501 SILVERSIDE ROAD SUITE 87AVA WILMINGTON DE 19809
Business Address 501 SILVERSIDE ROAD SUITE 87AVA WILMINGTON DE 19809 (302) 992-8882
GKCC, LLC (Filed by) CIK: 0001977769 (see all company filings)

EIN.: 472175589 | State of Incorp.: DE
Type: SCHEDULE 13D/A